Hermans, C. and Makris, M. orcid.org/0000-0001-7622-7939 (2021) Disruptive technology and hemophilia care : the multiple impacts of emicizumab. Research and Practice in Thrombosis and Haemostasis, 5 (4). e12508.
Abstract
Emicizumab, a bispecific antibody mimicking the action of factor VIII (FVIII), is currently the first and only approved and increasingly accessible disruptive treatment option for hemophilia A, a disease so far mainly treated with frequent intravenous infusions of FVIII concentrates or bypassing agents in case of inhibitor development. Other disruptive treatments are expected to follow, such as agents that rebalance coagulation and gene therapy with the ambition of curing hemophilia. While these treatment options represent major achievements or expectations, their adoption and implementation should consider their multiple direct and indirect, immediate or delayed, consequences on hemophilia care globally. It is these multiple changes, present and future, already visible or hypothetical, that this article intends to review and explore.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2021 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
Keywords: | care; disruptive technology; emicizumab; hemophilia; inhibitor; nonreplacement therapy |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Sheffield Teaching Hospitals |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 13 May 2021 06:40 |
Last Modified: | 21 Feb 2022 14:53 |
Status: | Published |
Publisher: | Wiley |
Refereed: | Yes |
Identification Number: | 10.1002/rth2.12508 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:174063 |
Download
Filename: Disruptive technology and hemophilia care The multiple impacts of emicizumab.pdf
Licence: CC-BY-NC-ND 4.0